TrialClinical and translational science2023

A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.

Jason Lickliter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.